ES3041322T3 - Novel mek-inhibitor for the treatment of viral and bacterial infections - Google Patents
Novel mek-inhibitor for the treatment of viral and bacterial infectionsInfo
- Publication number
- ES3041322T3 ES3041322T3 ES21185183T ES21185183T ES3041322T3 ES 3041322 T3 ES3041322 T3 ES 3041322T3 ES 21185183 T ES21185183 T ES 21185183T ES 21185183 T ES21185183 T ES 21185183T ES 3041322 T3 ES3041322 T3 ES 3041322T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- bacterial
- virus
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100487 | 2017-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3041322T3 true ES3041322T3 (en) | 2025-11-11 |
Family
ID=60484427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21185183T Active ES3041322T3 (en) | 2017-10-17 | 2018-10-17 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| ES18800045T Active ES2883639T3 (es) | 2017-10-17 | 2018-10-17 | Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18800045T Active ES2883639T3 (es) | 2017-10-17 | 2018-10-17 | Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11903917B2 (https=) |
| EP (2) | EP3973960B1 (https=) |
| JP (3) | JP7227967B2 (https=) |
| KR (1) | KR102848960B1 (https=) |
| CN (2) | CN118141795A (https=) |
| AU (2) | AU2018351475A1 (https=) |
| CA (1) | CA3078424A1 (https=) |
| CY (1) | CY1124507T1 (https=) |
| DK (1) | DK3697405T3 (https=) |
| EA (1) | EA202090693A1 (https=) |
| ES (2) | ES3041322T3 (https=) |
| HR (1) | HRP20211252T1 (https=) |
| HU (1) | HUE055738T2 (https=) |
| LT (1) | LT3697405T (https=) |
| MX (2) | MX2020003473A (https=) |
| PL (1) | PL3697405T3 (https=) |
| PT (1) | PT3697405T (https=) |
| SI (1) | SI3697405T1 (https=) |
| WO (1) | WO2019076947A1 (https=) |
| ZA (1) | ZA202002069B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| KR20220074869A (ko) | 2019-08-27 | 2022-06-03 | 아트리바 테라퓨틱스 게엠베하 | Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합 |
| JP7802365B2 (ja) * | 2019-10-08 | 2026-01-20 | アトリバ セラピューティクス ゲーエムベーハー | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| CN112957361B (zh) * | 2021-03-24 | 2022-07-29 | 中国科学院武汉病毒研究所 | 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| KR20020012315A (ko) * | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| DE10017480A1 (de) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| JP2007055983A (ja) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| CA2807510A1 (en) * | 2010-08-05 | 2012-02-09 | Case Western Reserve University | Inhibitors of erk for developmental disorders of neuronal connectivity |
| WO2014056894A1 (en) | 2012-10-08 | 2014-04-17 | Westfaelische Wilhelms-Universitaet Muenster | Mek inhibitors in the treatment of virus diseases |
| CN113398271A (zh) * | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| JP7802365B2 (ja) | 2019-10-08 | 2026-01-20 | アトリバ セラピューティクス ゲーエムベーハー | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
| EP3912623B1 (en) | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2018
- 2018-10-17 EP EP21185183.7A patent/EP3973960B1/en active Active
- 2018-10-17 ES ES21185183T patent/ES3041322T3/es active Active
- 2018-10-17 EP EP18800045.9A patent/EP3697405B1/en active Active
- 2018-10-17 JP JP2020521541A patent/JP7227967B2/ja active Active
- 2018-10-17 HU HUE18800045A patent/HUE055738T2/hu unknown
- 2018-10-17 MX MX2020003473A patent/MX2020003473A/es unknown
- 2018-10-17 HR HRP20211252TT patent/HRP20211252T1/hr unknown
- 2018-10-17 SI SI201830351T patent/SI3697405T1/sl unknown
- 2018-10-17 LT LTEPPCT/EP2018/078335T patent/LT3697405T/lt unknown
- 2018-10-17 PL PL18800045T patent/PL3697405T3/pl unknown
- 2018-10-17 ES ES18800045T patent/ES2883639T3/es active Active
- 2018-10-17 WO PCT/EP2018/078335 patent/WO2019076947A1/en not_active Ceased
- 2018-10-17 DK DK18800045.9T patent/DK3697405T3/da active
- 2018-10-17 KR KR1020207013451A patent/KR102848960B1/ko active Active
- 2018-10-17 CN CN202410133936.5A patent/CN118141795A/zh active Pending
- 2018-10-17 PT PT188000459T patent/PT3697405T/pt unknown
- 2018-10-17 US US16/756,720 patent/US11903917B2/en active Active
- 2018-10-17 EA EA202090693A patent/EA202090693A1/ru unknown
- 2018-10-17 CA CA3078424A patent/CA3078424A1/en active Pending
- 2018-10-17 CN CN201880081184.5A patent/CN111479566B/zh active Active
- 2018-10-17 AU AU2018351475A patent/AU2018351475A1/en not_active Abandoned
-
2020
- 2020-05-04 ZA ZA2020/02069A patent/ZA202002069B/en unknown
- 2020-07-13 MX MX2022016066A patent/MX2022016066A/es unknown
-
2021
- 2021-08-24 CY CY20211100757T patent/CY1124507T1/el unknown
-
2023
- 2023-02-10 JP JP2023018912A patent/JP7618276B2/ja active Active
-
2024
- 2024-02-16 US US18/443,904 patent/US20240245637A1/en active Pending
- 2024-08-16 AU AU2024205853A patent/AU2024205853A1/en active Pending
- 2024-12-25 JP JP2024228526A patent/JP2025031917A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3041322T3 (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| US11135263B2 (en) | Novel-anti-infective strategy against influenza virus and S. aureus coinfections | |
| ES3012533T3 (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| BR112020007442B1 (pt) | Uso de PD-0184264 ou um sal farmaceuticamente aceitável do mesmo e composições farmacêuticas | |
| EA047137B1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций | |
| HK40029715B (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| Barlow et al. | Infectious diseases and tropical medicine |